Summary of Accounting Pronouncements and Significant Accounting Policies Significant Accounting Policies [Text Block] Statistical Measurement [Domain] Statistical Measurement [Domain] Cash paid for amounts included in the measurement of lease liabilities: Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract] Cash paid for amounts included in the measurement of lease liabilities. Schedule of Available-for-Sale Marketable Securities Debt Securities, Available-for-Sale [Table Text Block] Award Timing Predetermined Award Timing Predetermined [Flag] Remainder of 2025 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Entity File Number Entity File Number Additional Paid-in Capital Additional Paid-in Capital [Member] Tabular List, Table Tabular List [Table Text Block] Leases [Abstract] Leases [Abstract] Updated Research Timelines Updated Research Timelines [Member] Updated Research Timelines Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] One-Time Cash Termination Fee One-Time Cash Termination Fee [Member] One-Time Cash Termination Fee Type of Restructuring [Domain] Type of Restructuring [Domain] Royalty payment Payments for Royalties License License [Member] Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Basic (in dollars per share) Earnings Per Share, Basic Adjustment to Compensation: Adjustment to Compensation [Axis] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Accounts payable and accrued liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Common stock reserved for issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Income Statement And Statement Of Comprehensive Income [Abstract] Income Statement And Statement Of Comprehensive Income Summary of reportable segment financial information Schedule of Segment Reporting Information, by Segment [Table Text Block] Common stock, shares issued (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Revenue, remaining performance obligation Revenue, Remaining Performance Obligation, Amount Adjustment to Compensation, Amount Adjustment to Compensation Amount Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Annual payment for license Annual License Fee Payment Annual License Fee Payment Stock options Share-Based Payment Arrangement, Option [Member] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Schedule Of Property Plant And Equipment [Table] Property, Plant and Equipment [Table] Commitments And Contingencies [Table] Commitments And Contingencies [Table] Commitments And Contingencies Antidilutive Securities [Axis] Antidilutive Securities [Axis] Total stockholders’ equity Beginning balance Ending balance Equity, Attributable to Parent Measurement Frequency [Axis] Measurement Frequency [Axis] Insider Trading Policies and Procedures [Line Items] Compensation expense Share-Based Payment Arrangement, Expense Schedule of Property, Equipment and Leasehold Improvements Property, Plant and Equipment [Table Text Block] Common stock issued, net of issuance costs (in shares) Stock Issued During Period, Shares, New Issues Current assets: Assets, Current [Abstract] Cancelled/ Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Total liabilities and stockholders’ equity Liabilities and Equity Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Fair Value, Measurements, Recurring Fair Value, Recurring [Member] Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Risks and Uncertainties Concentration Risk, Credit Risk, Policy [Policy Text Block] Sales Based Milestone Payments Sales Based Milestone Payments [Member] Sales-based milestone payments. Liabilities and stockholders' equity Liabilities and Equity [Abstract] Other income Other Nonoperating Income (Expense) [Abstract] Cover [Abstract] Cover [Abstract] Future grant of incentive units to service providers percentage Future Grant Of Incentive Units To Service Providers Percentage Future grant of incentive units to service providers, percentage. Maximum Maximum Maximum [Member] General and Administrative Expense General and Administrative Expense [Member] Vested and exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Schedule Of Equity Method Investments [Table] Equity Method Investment [Table] Accounting Policies [Abstract] Accounting Policies [Abstract] Proceeds from exercise of stock options and issuance of ESPP shares Proceeds From Exercise Of Stock Options And Issuance Of Employee Stock Shares Proceeds From Exercise Of Stock Options And Issuance Of Employee Stock Shares Schedule of Maturities of Operating Lease Liabilities Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Debt Instrument [Line Items] Debt Instrument [Line Items] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Treasury Treasury Stock, Common [Member] Total fair value of RSUs vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Pay vs Performance Disclosure [Line Items] Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Total Operating Lease, Liability Additions Accounts Receivable, After Allowance For Credit Loss, Current, Additions Accounts Receivable, After Allowance For Credit Loss, Current, Additions Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Depreciation and amortization Depreciation and amortization expense Depreciation, Depletion and Amortization, Nonproduction Net loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Entity Shell Company Entity Shell Company Debt Instrument [Table] Schedule of Long-Term Debt Instruments [Table] Beginning balance Ending balance Accounts Payable, Contract Balances, Current Accounts Payable, Contract Balances, Current Proceeds from disposal of property, equipment and leaseholds improvements Proceeds from Sale of Property, Plant, and Equipment Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Oerth Oerth Bio Limited Liability Corporation [Member] Oerth Bio LLC. Less: current installments Long-Term Debt, Current Maturities Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Company Selected Measure Amount Company Selected Measure Amount 2028 Lessee, Operating Lease, Liability, to be Paid, Year Three Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Name Measure Name Restructuring accrual Restructuring Reserve Current portion of operating lease liabilities Operating Lease, Liability, Current Debt instrument interest payments term (in months) Debt Instrument Interest Payments Term Debt instrument interest payments term. Document Fiscal Period Focus Document Fiscal Period Focus Award Timing Method Award Timing Method [Text Block] Award Type [Axis] Award Type [Axis] Deferred revenue Contract with Customer, Liability, Noncurrent Total Long-Term Debt Development Milestone Payments Development Milestone Payments [Member] Development milestone payments. Legal Entity [Axis] Legal Entity [Axis] Total assets Assets Equity Distribution Agreement Equity Distribution Agreement [Member] Equity distribution agreement. Investment, Name [Domain] Investment, Name [Domain] Trading Symbol Trading Symbol 2029 Lessee, Operating Lease, Liability, to be Paid, Year Four Required milestone payments Required Milestone Payments Required Milestone Payments Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Contract liabilities: Deferred revenue Change in Contract with Customer, Liability [Roll Forward] Change in Contract with Customer, Liability Geographical [Domain] Geographical [Domain] Amortization Capitalized Contract Cost, Amortization During Period Capitalized Contract Cost, Amortization During Period Issuance of common stock under equity incentive plans (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Entity Address, City or Town Entity Address, City or Town Cash flows from operating activities: Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Other segment expense, net Segment Reporting, Other Segment Item, Amount Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Statement of Income Location, Balance [Domain] Statement of Income Location, Balance [Domain] RSUs Restricted Stock Units (RSUs) [Member] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Contract Termination [Domain] Contract Termination [Domain] Contract Termination [Domain] Entity Emerging Growth Company Entity Emerging Growth Company 2028 Long-Term Debt, Maturity, Year Three Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Right-of-use assets obtained in exchange for new lease obligations Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Beginning balance (in shares) Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Level 2 Fair Value, Inputs, Level 2 [Member] Equity method investments Equity Method Investments Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Common stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Piper Sandler and Cantor Piper Sandler And Cantor [Member] Piper sandler and cantor. 101 College Street LLC 101 College Street LLC [Member] 101 College Street LLC Plan Name [Axis] Plan Name [Axis] PEO PEO [Member] Employee Severance Employee Severance [Member] License Second Licensed Product License Second Licensed Product [Member] License Second Licensed Product Other programs Other Programs [Member] Other Programs Contingent payments Revenue, Remaining Performance Obligation, Contingent Payments Revenue, Remaining Performance Obligation, Contingent Payments Interest income, net Interest income, net Investment Income, Interest Income taxes Accrued Income Taxes, Current Changes in operating assets and liabilities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Novartis Pharma AG Novartis Pharma AG [Member] Novartis Pharma AG Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Accumulated Deficit Retained Earnings [Member] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Schedule of Components of Accounts Payable and Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Restatement Determination Date Restatement Determination Date Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Cash, cash equivalents and restricted cash, beginning of the period Cash and cash equivalents, end of the period Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Income Statement [Abstract] Income Statement [Abstract] Income tax expense Income tax expense Income tax expense Income Tax Expense (Benefit) Number of inducement grants (in shares) Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Inducement Grants Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Inducement Grants Purchases of marketable securities Payments to Acquire Marketable Securities Sale of Stock [Domain] Sale of Stock [Domain] Collaboration agreement direct and incremental costs incurred Direct And Incremental Costs Incurred To Obtain The Contract Direct and incremental costs incurred to obtain the contract. Aggregate Intrinsic Value Aggregate Intrinsic Value [Abstract] Aggregate Intrinsic Value Annual increase in reserved shares of common stock (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Other Increases (Decreases) in Period Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Payments for collaboration Payments For Collaboration Payments For Collaboration Product and Service [Domain] Product and Service [Domain] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Vested and expected to vest (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Total property, equipment and leasehold improvements Property, Plant and Equipment, Gross Cash, cash equivalents, restricted cash and marketable securities Cash, Cash Equivalents, Restricted Cash and Marketable Securities Cash, Cash Equivalents, Restricted Cash and Marketable Securities Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Pre-Funded Warrant Pre-Funded Warrant [Member] Pre-Funded Warrant Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Restructuring Activity Restructuring and Related Activities Disclosure [Text Block] Amortization of right-of-use assets Operating Lease, Right-of-Use Asset, Periodic Reduction Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] City Area Code City Area Code Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Payments received Proceeds from Collaborators All Trading Arrangements All Trading Arrangements [Member] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Program-specific external expense Research And Development Expense, Program Specific Research And Development Expense, Program Specific Beginning balance (in shares) Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Commitments and Contingencies Disclosure [Abstract] Schedule of Contract Balances Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Cash flows from investing activities: Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] General and administrative General and administrative expense General and Administrative Expense Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Net cash used in operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Equity Method Investments and Joint Ventures [Abstract] Equity Method Investments and Joint Ventures [Abstract] ARV-102 ARV-102 [Member] ARV-102 Preferred stock par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Schedule of Assumptions Used to Determine Fair Value of Stock Options Granted Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule Of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Schedule of Components of Lease Expense Lease, Cost [Table Text Block] PEO Total Compensation Amount PEO Total Compensation Amount Equity Components [Axis] Equity Components [Axis] Property Plant And Equipment [Line Items] Property, Plant and Equipment [Line Items] 2018 Assistance Agreement Two Thousand And Eighteen Assistance Agreement [Member] Two thousand and eighteen assistance agreement. Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] License First Licensed Product License First Licensed Product [Member] License First Licensed Product Number of reportable segments Number of Reportable Segments Removal of Combination Trials Removal Of Combination Trials [Member] Removal Of Combination Trials Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Other Performance Measure, Amount Other Performance Measure, Amount Entity Address, State or Province Entity Address, State or Province Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Total current liabilities Liabilities, Current Reduction in workforce (as a percent) Restructuring and Related Cost, Number of Positions Eliminated, Period Percent Commercial Milestones Commercial Milestones [Member] Commercial milestones. Collaboration contract asset and other assets Collaboration Contract Asset And Other Assets Collaboration contract asset and other assets. Accounts payable related to collaborations Change in Accounts Payable, after Allowance for Credit Loss [Roll Forward] Change in Accounts Payable, after Allowance for Credit Loss Individual: Individual [Axis] Reportable Segment Reportable Segment [Member] Reportable Segment Success-Based Milestone Payments Success-Based Milestone Payments [Member] Success-Based Milestone Payments Other receivables Increase (Decrease) in Other Receivables Research and Development Expense Research and Development Expense [Member] Change in Accounting Estimate by Type [Axis] Effect of Change in Accounting Estimate, Type [Axis] Entity [Domain] Entity [Domain] Net cash provided by (used in) investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Revenue, remaining performance obligation, expected timing of satisfaction, period Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Document Fiscal Year Focus Document Fiscal Year Focus Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] 2018 Plan 2018 Plan Two Thousand Eighteen Stock Incentive Plan [Member] Two thousand eighteen stock incentive plan. Repayments of long-term debt Repayments of Long-Term Debt Effective tax rate, percentage Effective Income Tax Rate Reconciliation, Percent Entity Interactive Data Current Entity Interactive Data Current Operating lease cost Operating Lease, Cost Revenue recognized from new collaborations Contract with Customer, Liability, Revenue Recognized From New Collaboration Contract with Customer, Liability, Revenue Recognized From New Collaboration Plan Name [Domain] Plan Name [Domain] Additions to collaboration agreements Contract With Customer, Liability, Increase (Decrease) For Additions To Collaboration Agreements Contract With Customer, Liability, Increase (Decrease) For Additions To Collaboration Agreements Compensation expense not yet recognized, period of recognition (in years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Vested and exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Less: Segment Reconciliation [Abstract] Segment Information Segment Reporting Disclosure [Text Block] Vepdegestrant ARV-471 ARV-471 [Member] ARV-471 Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Weighted Average Weighted Average [Member] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value, Recurring and Nonrecurring [Table] Entity Central Index Key Entity Central Index Key PEO Name PEO Name Schedule of Minimum Future Payments on Long-Term Debt Schedule of Maturities of Long-Term Debt [Table Text Block] Revenue Revenue Revenues Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Supplemental non-cash information: Supplemental Non Cash Information Related To Leases [Abstract] Supplemental non-cash information related to leases. Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Arrangement Duration Trading Arrangement Duration Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Research Funding Payments Research Funding Payments [Member] Research funding payments. ARV-806 ARV-806 [Member] ARV-806 Expected volatility, maximum (percentage) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Deferred revenue Contract with Customer, Liability, Current Segments [Axis] Segments [Axis] Warrant exercise price (in usd per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Exercise Price Award Exercise Price Entity Filer Category Entity Filer Category Local Phone Number Local Phone Number Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Federal statutory rate, percentage Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Leasehold improvement written-off Property, Plant And Equipment, Writeoff Property, Plant And Equipment, Writeoff Equity Share-Based Payment Arrangement [Text Block] Maturities of marketable securities Proceeds From Maturities Of Marketable Securities Proceeds from maturities of marketable securities. Assets Assets [Abstract] Long-term debt Total long-term debt Long-Term Debt, Excluding Current Maturities Underlying Security Market Price Change Underlying Security Market Price Change, Percent Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Debt Instrument [Axis] Debt Instrument [Axis] Cancelled/ Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Marketable Securities and Fair Value Measurements Fair Value Disclosures [Text Block] Stockholders’ equity: Equity, Attributable to Parent [Abstract] Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Share repurchases (treasury stock) Treasury Stock, Value, Acquired, Cost Method Research and development Total research and development expense Research and Development Expense Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Investment, Name [Axis] Investment, Name [Axis] Interest Rate Debt instrument bearing interest rate Debt Instrument, Interest Rate, Stated Percentage Operating lease liabilities Operating Lease, Liability, Noncurrent Loan forgiveness Debt Instrument Loan Forgiveness Debt instrument loan forgiveness. General and administrative and commercial expenses Accrued General And Administrative And Commercial, Current Accrued General And Administrative And Commercial, Current Genentech Genentech Incorporation And F Hoffman La Roche Limited [Member] Genentech, Incorporation. and F. Hoffman-La Roche Limited. Research Collaboration And License Agreements [Line Items] Research Collaboration And License Agreements [Line Items] Research collaboration and license agreements. Fair Value as of Grant Date Award Grant Date Fair Value Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Entity Registrant Name Entity Registrant Name Percentage of liquidated damages Percentage Of Liquidated Damages Percentage of liquidated damages. Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Compensation and related personnel expense (including stock-based compensation) Labor and Related Expense Schedule of Long-Term Debt Schedule of Long-Term Debt Instruments [Table Text Block] Milestone Payment Upon Approval of First and Second Royalty Products Milestone Payment Upon Approval Of First And Second Royalty Products [Member] Milestone Payment Upon Approval Of First And Second Royalty Products Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Cancelled/ Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Compensation expense not yet recognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Document Quarterly Report Document Quarterly Report Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Counterparty Name [Domain] Counterparty Name [Domain] Number of operating segments Number of Operating Segments 2027 Lessee, Operating Lease, Liability, to be Paid, Year Two Net accretion of bond discounts/premiums Accretion (Amortization) of Discounts and Premiums, Investments Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Outstanding (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Milestone payments achieved, amount due Milestone Payments Achieved, Amount Due Milestone Payments Achieved, Amount Due Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Title Trading Arrangement, Individual Title Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Restatement Determination Date: Restatement Determination Date [Axis] Issuance of common stock under equity incentive plans Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Non-PEO NEO Non-PEO NEO [Member] Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Collaboration Agreement Collaboration Agreement [Member] Collaboration agreement. Sale of Stock [Axis] Sale of Stock [Axis] Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Repurchases of common shares unpaid at period end Repurchases Of Common Shares Unpaid At Period End Repurchases Of Common Shares Unpaid At Period End Name Trading Arrangement, Individual Name Award Type [Domain] Award Type [Domain] 2026 Lessee, Operating Lease, Liability, to be Paid, Year One Equity Awards Adjustments Equity Awards Adjustments [Member] Leasehold improvements Leasehold Improvements [Member] Payments made Accounts Payable, Contract Balances, Current Payments Accounts Payable, Contract Balances, Current Payments Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Common stock aggregate offering price Maximum Aggregate Offering Price Of Common Stock Maximum aggregate offering price of common stock. Compensation Amount Outstanding Recovery Compensation Amount Debt instrument face amount Debt Instrument, Face Amount Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Expected dividend yield (percentage) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Condensed Consolidated Statements of Comprehensive Income (Loss) Statement of Comprehensive Income [Abstract] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Revenue recognized from balances held at the beginning of the period Contract with Customer, Liability, Revenue Recognized Issuance of common stock for pre-funded warrants (in shares) Stock Issued During Period, Shares, Exercise Of Warrants Stock Issued During Period, Shares, Exercise Of Warrants MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Name Awards Close in Time to MNPI Disclosures, Individual Name Beginning balance (in dollars per share) Ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Restructuring Type [Axis] Restructuring Type [Axis] Weighted average common shares outstanding Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] ESPP Employee Stock [Member] Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Treasury Stock, at cost (2.6 and zero shares at September 30, 2025 and December 31, 2024, respectively) Treasury Stock, Value Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax 2026 Long-Term Debt, Maturity, Year One Vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Financial Instruments [Domain] Financial Instruments [Domain] Segments [Domain] Segments [Domain] Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Axis] Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Yale University Yale University [Member] Yale University Schedule of Transaction Price Allocated to Performance Obligations Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Share repurchase program, commissions and excise tax Share Repurchase Program Commissions And Excise Tax Share Repurchase Program Commissions And Excise Tax Warrants to be purchased (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Minimum Minimum [Member] Research Collaboration And License Agreements [Abstract] Research Collaboration And License Agreements Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Company Selected Measure Name Company Selected Measure Name Government securities US Government Debt Securities [Member] Payments received Accounts Receivable, After Allowance For Credit Loss, Current, Payments Received Accounts Receivable, After Allowance For Credit Loss, Current, Payments Received Long-Term Debt Debt Disclosure [Text Block] Preferred stock, $0.001 par value, zero shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively Preferred Stock, Value, Issued Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Accounts payable Accounts Payable, Current Operating cash flows from operating leases Operating Lease, Payments Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] All Executive Categories All Executive Categories [Member] Common stock, $0.001 par value; 73.4 shares issued, 70.8 shares outstanding as of September 30, 2025 and 68.8 shares issued and outstanding as of December 31, 2024 Common Stock, Value, Issued Expected volatility, minimum (percentage) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Diluted (in shares) Weighted average common shares outstanding - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Commitments and Contingencies (Note 13) Commitments and Contingencies Contract assets: Collaboration contract asset Change in Collaboration Contract Asset And Other Assets [Roll Forward] Change in Collaboration Contract Asset And Other Assets Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Entity Small Business Entity Small Business Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Inducement grants (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Inducement Grants Share-Based Compensation Arrangement by Share-Based Payment Award, Inducement Grants Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Document Transition Report Document Transition Report Ownership interest, percentage Equity Method Investment, Ownership Percentage Underlying Securities Award Underlying Securities Amount Equity Component [Domain] Equity Component [Domain] Document Period End Date Document Period End Date PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Bayer LP Bayer Crop Science L P [Member] Bayer CropScience LP. Income Taxes Income Tax Disclosure [Text Block] Research and development expenses Accrued Research And Development Expense Current Accrued research and development expense current. Option Payments To License Agreement Option Payments To License Agreement [Member] Option payments to license agreement. Accounts receivable related to collaborations Change in Accounts Receivable, after Allowance for Credit Loss [Roll Forward] Change in Accounts Receivable, after Allowance for Credit Loss Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Regulatory and Sales-Based Milestones Regulatory And Sales Based Milestones [Member] Regulatory and sales-based milestones. Schedule of Supplemental Cash Flow Information Related to Leases Schedule Of Supplemental Cash Flow Information Related To Leases [Table Text Block] Supplemental cash flow information related to leases. Stock Compensation And Bonus Expense Stock Compensation And Bonus Expense [Member] Stock Compensation And Bonus Expense Vested and exercisable (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Contract Termination [Axis] Contract Termination [Axis] Contract Termination Operating lease liability Increase (Decrease) in Operating Lease Liability Share repurchase program, average price (in dollars per share) Shares Acquired, Average Cost Per Share Bayer Collaboration Agreement Bayer A G [Member] Bayer AG. Document Type Document Type Loss Per Common Share Earnings Per Share [Text Block] Name Outstanding Recovery, Individual Name Additional paid-in capital Additional Paid in Capital Office equipment Office Equipment [Member] Product and Service [Axis] Product and Service [Axis] Revenue recognized Revenue from Contract with Customer, Excluding Assessed Tax All Individuals All Individuals [Member] Change in Accounting Estimate, Type [Domain] Effect of Change in Accounting Estimate, Type [Domain] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Purchases of property, equipment and leasehold improvements Payments to Acquire Property, Plant, and Equipment Vested and expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Name Forgone Recovery, Individual Name Total current assets Assets, Current Statistical Measurement [Axis] Statistical Measurement [Axis] Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Share repurchase program, authorized amount Share Repurchase Program, Authorized, Amount Other receivables Other Receivables, Net, Current Annual increase in reserved shares as percentage of outstanding common stock Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Intrinsic value of options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Capitalized costs Capitalized Contract Cost, Gross Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Marketable securities Marketable Securities, Current Lease for laboratory and office space (in sq feet) Land Subject to Ground Leases Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Writeoff of Prepaid Rent Writeoff Of Prepaid Rent [Member] Writeoff Of Prepaid Rent Current liabilities: Liabilities, Current [Abstract] Weighted Average Remaining Contractual Term (Years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Geographical [Axis] Geographical [Axis] Lessee Lease Description [Line Items] Lessee, Lease, Description [Line Items] Total operating expenses Operating expenses Operating Expenses Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] State of Connecticut CONNECTICUT Risk free interest rate, minimum (percentage) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Diluted (in dollars per share) Earnings Per Share, Diluted Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Accounts receivable Beginning balance Ending balance Accounts Receivable, after Allowance for Credit Loss, Current Title of 12(b) Security Title of 12(b) Security Lessee Lease Description [Table] Lessee, Lease, Description [Table] Amortization of collaboration contract asset Capitalized Contract Cost, Amortization Other comprehensive loss: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Treasury stock (in shares) Beginning balance (in shares) Ending balance (in shares) Treasury Stock, Common, Shares Sales-Based Milestones Sales Based Milestones [Member] Sales-based milestones. Loss per common share Earnings Per Share [Abstract] Nature of Business and Basis of Presentation Business Description and Basis of Presentation [Text Block] Total other income Nonoperating Income (Expense) Common stock reserved for issuance represented as percentage on outstanding common stock Increase In Capital Shares Reserved For Future Issuance Represented As Percentage On Outstanding Common Stock Increase in capital shares reserved for future issuance represented as percentage on outstanding common stock. Equity Method Investments Equity Method Investments and Joint Ventures Disclosure [Text Block] Additions Accounts Payable, Contract Balances, Current Additions Accounts Payable, Contract Balances, Current Additions Schedule of Securities Excluded From Computation of Diluted Net Loss Per Common Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Deferred revenue Increase (Decrease) in Contract with Customer, Liability Accounts Payable and Accrued Liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Milestone payment the Company will make Collaborative Arrangement, Rights And Obligations, Milestone Payment Collaborative Arrangement, Rights And Obligations, Milestone Payment Exercise price (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price Less: imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Cash paid for taxes Income Taxes Paid, Net Share repurchases (treasury stock) (in shares) Stock repurchased (in shares) Treasury Stock, Shares, Acquired Corporate bonds Corporate Bond Securities [Member] Schedule of Restricted Stock Grant Activity Nonvested Restricted Stock Shares Activity [Table Text Block] Share repurchase program, acquired, value net of commissions Treasury Stock, Value, Acquired, Cost Method, Net Of Commissions Treasury Stock, Value, Acquired, Cost Method, Net of Commissions Award Timing Disclosures [Line Items] Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Employee expenses Employee-related Liabilities, Current Measurement Frequency [Domain] Measurement Frequency [Domain] Bavdegalutamide (ARV-110) ARV-110 [Member] ARV-110 Property, Equipment and Leasehold Improvements Property, Plant and Equipment Disclosure [Text Block] Total lease payments Lessee, Operating Lease, Liability, to be Paid Other research and development expense Other Research and Development Expense Non program-specific external expense Research And Development Expense, Non-Program Specific Research And Development Expense, Non-Program Specific Net loss Net loss Net loss Segment net loss Net Income (Loss) Attributable to Parent Pfizer, Inc. Pfizer Incorporation [Member] Pfizer, Incorporation. Expiration Date Trading Arrangement Expiration Date Research Collaboration And License Agreements [Table] Research Collaboration And License Agreements [Table] Research collaboration and license agreements. Unrealized gain on available-for-sale securities Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Property, equipment and leasehold improvements, net Property, equipment and leasehold improvements, net Property, Plant and Equipment, Net Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Restructuring charges (income) Restructuring Charges Repurchase of common shares Payments for Repurchase of Common Stock Adoption Date Trading Arrangement Adoption Date Vested and expected to vest (in Years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Accounts receivable Increase (Decrease) in Accounts Receivable Contract revenue receivable if milestones achieved Beginning balance Ending balance Contract with Customer, Asset, after Allowance for Credit Loss Restructuring Cost [Table] Restructuring Cost [Table] Entity Current Reporting Status Entity Current Reporting Status Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Loss from operations Operating Income (Loss) Accumulated deficit Retained Earnings (Accumulated Deficit) Number of licensed products Number of Licensed Products Number of Licensed Products Upfront Payment for Amended License Agreement and Novartis License and Asset Agreements Upfront Payment For Amended License Agreement And Novartis License And Asset Agreements [Member] Upfront Payment For Amended License Agreement And Novartis License And Asset Agreements Net loss on disposal of property, plant and equipment Gain (Loss) on Disposition of Property Plant Equipment Financial Instrument [Axis] Financial Instrument [Axis] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Executive Category: Executive Category [Axis] Decrease in compensation expense Share-Based Payment Arrangement, Plan Modification, Incremental Cost Current Fiscal Year End Date Current Fiscal Year End Date Expected term (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Payables and Accruals [Abstract] Payables and Accruals [Abstract] Weighted Average Grant Date Fair Value Per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Common stock, shares remained available for purchase (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Statement [Table] Statement [Table] Other expense, net Other Nonoperating Income (Expense) Adjustments to reconcile net loss to net cash used in operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Research Collaboration and License Agreements Collaborative Arrangement Disclosure [Text Block] Cash flows from financing activities: Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Weighted-average grant date fair value of options (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Luxdegalutamide (ARV-766) ARV-766 [Member] ARV-766 Milestone Payment on First Anniversary of Signing Milestone Payment On First Anniversary Of Signing [Member] Milestone Payment On First Anniversary Of Signing Contract with customer, liability Beginning balance Ending balance Contract with Customer, Liability Antidilutive securities excluded from computation of diluted net loss per common share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount All Adjustments to Compensation All Adjustments to Compensation [Member] ARV-393 ARV-393 [Member] ARV-393 Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Table] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Accounts payable and accrued liabilities Total accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities, Current Amendment Flag Amendment Flag 2027 Long-Term Debt, Maturity, Year Two Regulatory Milestone Related to Marketing Approvals Regulatory Milestone Payments [Member] Regulatory milestone payments. Right-of-Use Assets and Liabilities Lessee, Operating Leases [Text Block] Termination Date Trading Arrangement Termination Date Net cash (used in) provided by financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Collaboration contract asset Increase (Decrease) in Contract with Customer, Asset Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Accrued liabilities Accrued Liabilities [Abstract] Measure: Measure [Axis] Schedule of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Basic (in shares) Weighted average common shares outstanding - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Share repurchase program, remaining authorized amount Share Repurchase Program, Remaining Authorized, Amount Schedule of Basic and Diluted Loss per Common Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Percentage of incremental borrowing for lease payments Percentage Of Incremental Borrowing For Lease Payments Percentage of incremental borrowing for lease payments. Vested and exercisable, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Segment Reporting [Abstract] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Entity Tax Identification Number Entity Tax Identification Number Additions Contract With Customer, Assets, Increase (Decrease) For Additions To Collaboration Agreements Contract With Customer, Assets, Increase (Decrease) For Additions To Collaboration Agreements Beginning balance (in dollars per share) Ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Restructuring and Related Activities [Abstract] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common stock, shares issued (in shares) Common Stock, Shares, Issued Total intrinsic value of RSUs released Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options, Aggregate Intrinsic Value, Released In Period Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options, Aggregate Intrinsic Value, Released In Period Operating lease, weighted average remaining lease term (in years) Operating Lease, Weighted Average Remaining Lease Term Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Laboratory equipment Laboratory Equipment [Member] Laboratory equipment. At-the-Market Offering At The Market Offering [Member] At the market offering. Use of Estimates Use of Estimates, Policy [Policy Text Block] Trading Arrangement: Trading Arrangement [Axis] Total Shareholder Return Amount Total Shareholder Return Amount Insider Trading Arrangements [Line Items] Security Exchange Name Security Exchange Name Cancelled/ Forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Remainder of 2025 Long-Term Debt, Maturity, Remainder of Fiscal Year Total liabilities Liabilities Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Loss per common share Earnings (Loss) Per Common Share, EPS [Abstract] Earnings (Loss) Per Common Share, EPS Issuance of common stock for pre-funded warrants (in shares) Stock Issued During Period, Shares, Warrants Exercised Stock Issued During Period, Shares, Warrants Exercised Operating expenses: Operating Expenses [Abstract] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Lease termination costs Gain (Loss) on Contract Termination Statement [Line Items] Statement [Line Items] Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash and cash equivalents Cash and Cash Equivalent Counterparty Name [Axis] Counterparty Name [Axis] Risk free interest rate, maximum (percentage) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Common Common Stock [Member] Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Fair Value Debt Securities, Available-for-Sale Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Non-NEOs Non-NEOs [Member] Net increase (decrease) in cash and cash equivalents Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Professional fees Accrued Professional Fees, Current